Ms. Paige Comstock Cunningham  
Executive Director  
The Center for Bioethics and Human Dignity  
Trinity International University  
2065 Half Day Road  
Deerfield, IL 60015

March 23, 2016

Dear Ms. Cunningham:

Thank you for appearing before the Select Investigative Panel of the Committee on Energy and Commerce on Wednesday, March 2, 2016, to testify at the hearing entitled “Bioethics and Fetal Tissue.”

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Wednesday, April 6, 2016. Your responses should be mailed to Rachel Collins, Investigative Counsel and Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to Rachel.Collins@mail.house.gov.

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

Marsha Blackburn  
Chairman  
Select Investigative Panel of the Committee on Energy and Commerce

cc: The Honorable Janice D. Schakowsky, Ranking Member, Select Investigative Panel of the Committee on Energy and Commerce

Attachment
Attachment — Additional Questions for the Record

The Honorable Marsha Blackburn

1. In response to a question about “obtaining embryos on demand” (referencing Exhibit F), you testified that “my concern is that researchers have come to count on induced abortions for their research.”

   Please elaborate on what alternatives to fetal tissue from induced abortions are available to researchers.

   Also, are there other steps that could be taken to reduce researchers demand for fetal tissue from induced abortions without jeopardizing research?

2. In response to a question about whether a series of emails (Exhibits B1-B3) raised any ethical concerns, you testified that “it completely fails to isolate abortion from the decision about the fetal tissue and consent to use the fetal tissue” and that there was “no indication of consent prior to this procedure or for these specific parts to be excised.”

   What ethical concerns arise when there is a failure to isolate an abortion procedure from the patient consent obtained for fetal tissue donation prior to an abortion being performed?